{
    "name": "Amitriptyline",
    "genericName": "Elavil",
    "tags": [
        "TCA",
        "depression",
        "neuropathic pain",
        "migraine prevention",
        "insomnia"
    ],
    "dosing": {
        "adult_acute": "75-200 mg/day",
        "adult_maintenance": "50-150 mg/day",
        "notes": "Take at bedtime. Therapeutic drug monitoring available (target 80-200 ng/mL combined amitriptyline + nortriptyline). Widely used for pain and migraine at sub-antidepressant doses.",
        "canadian_clinical": {
            "starting_dose": "10-25 mg/day at bedtime",
            "titration_schedule": "Increase by 25 mg every 5-7 days as tolerated.",
            "inpatient_strategy": "Start 25-50 mg nocte. Titrate to 100-150 mg over 1-2 weeks targeting antidepressant effect.",
            "outpatient_strategy": "Start 10-25 mg nocte for tolerability. For pain/migraine: target 25-75 mg. For depression: target 100-200 mg.",
            "max_dose_evidence": "300 mg/day",
            "max_dose_practice": "200 mg/day (most clinicians limit here due to toxicity risk)."
        }
    },
    "cautions": {
        "renal": "No specific adjustment; monitor for accumulation.",
        "hepatic": "Avoid in severe hepatic impairment; reduce dose if mild-moderate.",
        "pregnancy": "Generally avoided; limited safety data, neonatal withdrawal possible."
    },
    "warnings": [
        "QTc prolongation — baseline and follow-up ECG recommended",
        "High lethality in overdose (cardiac arrhythmia)",
        "Heavy anticholinergic burden (dry mouth, constipation, urinary retention, delirium risk in elderly)",
        "Marked sedation",
        "Orthostatic hypotension — fall risk especially in elderly",
        "Lower seizure threshold",
        "Not recommended as first-line in elderly (Beers Criteria)"
    ],
    "citations": [
        "CANMAT Depression 2016",
        "Maudsley Prescribing Guidelines 14th ed",
        "NICE CKS Neuropathic Pain 2022"
    ]
}
